JBCHEPHARM - Swing Trade Analysis

Last Updated Time : 02 Aug 25, 12:58 am

Swing Trade Rating: 4.3

🚀 Technical Outlook

Price ₹1,803 is trading well above both 50 DMA (₹1,679) and 200 DMA (₹1,693) — confirms bullish trend continuation.

RSI (71.8) — strongly overbought, which typically suggests a short-term pullback or cooling-off.

MACD (12.9) — elevated and positive, confirms trend strength.

Volume spike (10.8L vs avg 4.9L) — strong buying momentum, supports breakout behavior.

📊 Fundamental Highlights

P/E (44.1) above Industry PE (34.0) — reflects premium valuation.

PEG Ratio (2.06) — priced high relative to growth; less ideal for value-conscious swing trades.

ROCE (25.8%) and ROE (20.1%) — healthy efficiency indicators.

EPS ₹42.4 — solid earnings base.

Debt-to-Equity: 0.01 — extremely low; adds stability.

Quarterly PAT Dip (₹162 Cr. → ₹146 Cr.) — modest decline, though not alarming given overall momentum.

🏦 Institutional Sentiment

FII Holding Change: –0.53% — some cooling from foreign funds.

DII Holding Change: +0.91% — domestic investors showing renewed interest.

🎯 Trade Strategy

📥 Optimal Entry (If Not Holding)

Wait for a pullback to ₹1,750–₹1,765 zone — near breakout support.

Enter only if

RSI cools to 65–67

MACD remains positive

Volume stabilizes near daily average

📤 Exit Plan (If Already Holding)

Initial Target Zone: ₹1,890–₹1,925 — recent resistance band.

Momentum Extension: ₹1,970–₹2,010 — achievable if RSI stays >70 and MACD slope persists.

Full Exit Point: ₹2,030+ — test previous high, exit if volume starts fading or bearish divergence appears.

🧠 Verdict

JBCHEPHARM is riding strong technical momentum with solid fundamentals and minimal debt. Though RSI signals possible short-term saturation, it remains a promising swing trade candidate if entered smartly near support zones and monitored for volume strength.

Want me to screen other pharma stocks hovering just below breakout zones with cleaner RSI setups? I’ve got a few worth peeking into.

Edit in a page